Cortexyme Appoints Dr. Philip Low to Its Board of Directors
May 20 2022 - 8:01AM
Business Wire
Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage
biopharmaceutical company pioneering therapeutic approaches to
improve the lives of patients diagnosed with degenerative diseases,
today announced the appointment of Dr. Philip S. Low, a renowned
targeted drug discovery researcher and veteran biotech
entrepreneur, to the company’s Board of Directors.
“In conjunction with today’s acquisition of Novosteo, we are
very pleased to welcome a distinguished researcher, innovator, and
entrepreneur of Dr. Philip Low’s caliber to our Board of
Directors,” said David Lamond, chairman of Cortexyme’s Board of
Directors. “His vast expertise across targeted drug discovery,
prolific research abilities, and proven track record as a leading
biotech entrepreneur further bolsters the scientific and clinical
expertise of the Board, following on the recent addition of
neurologist and leading expert in Alzheimer’s and dementia care Dr.
Marwan Sabbagh.”
“The Cortexyme team and I share the same passion for challenging
the status quo to deliver breakthrough therapeutics,” said Dr.
Philip Low. “I look forward to contributing my perspective at the
Board level as the newly combined company sets its strategic path
forward and delivers much needed innovation to patients suffering
from degenerative diseases.”
Dr. Philip S. Low is the Presidential Scholar in Drug Discovery
and the Ralph C. Corley Distinguished Professor of Chemistry at
Purdue University. Dr. Low has spent more than 30 years exploring
novel methods for targeted drug discovery, including target
identification, drug design and synthesis, animal testing, and
human clinical evaluation. He has published more than 500
scientific articles and has more than 360 U.S. patents and patents
pending. Eight drugs stemming from his research are currently
undergoing human clinical trials and seven companies (Endocyte
Inc., OnTarget Laboratories Inc., Novosteo Inc., Erythrocure Inc.,
Umoja Biopharma Inc., Morphimmune Inc. and Eradivir Inc.) have been
founded to commercialize these discoveries. Dr. Low has received an
NIH MERIT Award, the ACS Award for Cancer Research (Sosnovsky
Award), the AACR Award for Outstanding Chemistry in Cancer
Research, both of Purdue's awards for outstanding research (McCoy
and Sigma Xi Awards), the University’s highest career achievement
award (Morrill Award), the American Chemical Society’s Esselen
Award and numerous other National and International awards. Dr. Low
received his B.S. in Chemistry from Brigham Young University and
his PhD in Biochemistry from the University of California, San
Diego.
About Cortexyme
Cortexyme, Inc. (Nasdaq: CRTX) is a clinical stage
biopharmaceutical company dedicated to improving the lives of
patients diagnosed with degenerative diseases. The company’s
innovative pipeline includes a precision bone growth molecule and
drug-targeting platform to treat rare skeletal diseases, bone
cancer and injury, in addition to small molecule therapeutics
targeting the infectious pathogen P. gingivalis’ role in
degenerative disease progression, including for indications such as
periodontal disease, oral potentially malignant disorders, and
Alzheimer’s disease, among others. To learn more about Cortexyme,
visit www.cortexyme.com or follow @Cortexyme on Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220520005049/en/
Cortexyme Contact: Stacy Roughan Cortexyme, Inc. Vice
President, Corporate Communications & Investor Relations
ir@cortexyme.com
Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Sep 2023 to Sep 2024